Next-Generation Nanobody Targeting ALB and FCGRT for Innovative Autoimmune Disease Therapy

VHH-P257 is a novel, humanized nanobody therapeutically designed to target albumin (ALB) and the Fc gamma receptor and transporter (FCGRT), which play essential roles in immune regulation and protein homeostasis. Currently in the Biological Testing phase, VHH-P257 leverages specificity towards both ALB and FCGRT to offer a promising strategy for the management of autoimmune diseases. Its dual-target approach aims to modulate key pathways involved in pathogenic immune responses, positioning VHH-P257 as a potentially transformative therapeutic in the autoimmune field.

Licensing Opportunity

VHH-P257 is available for out-licensing and partnership opportunities. We welcome inquiries from companies and research organizations interested in advancing this differentiated nanobody program for autoimmune disease therapeutics.

Development Phase

Modality

VHH-P257 is a bivalent Fc fusion construct, consisting of a human IgG1 Fc region engineered with affinity-enhancing mutations, C-terminally fused via a flexible glycine-serine linker to a single-domain antibody (nanobody) specific for albumin. Produced in Chinese hamster ovary cells, this modality harnesses the structural advantages of nanobodies, such as small molecular size and robust stability, enabling superior tissue penetration and biophysical resilience. The unique architecture supports enhanced pharmacokinetic properties and targeted immune modulation, key requirements for effective management of autoimmune diseases where deep tissue access and precise immune intervention are critical.

Target

ALB and FCGRT are pivotal targets in immune modulation therapy. ALB is a major plasma protein responsible for maintaining oncotic pressure and transporting various biomolecules. FCGRT, a critical component of antibody recycling and homeostasis, regulates IgG half-life by mediating its transport and protection from lysosomal degradation. Both ALB and FCGRT are predominantly expressed in vascular endothelium, hepatocytes, and various immune-regulatory tissues. Their involvement in autoantibody production, immune complex clearance, and protein turnover makes ALB and FCGRT compelling targets for autoimmune disease intervention. By specifically directing activity toward ALB and FCGRT, VHH-P257 achieves strategic value in modulating immune dysregulation, providing a differentiated approach compared to conventional therapies.

Mechanism of Action

VHH-P257 functions as a dual-acting molecule by targeting both ALB and FCGRT. The binding to ALB facilitates prolonged serum half-life, while the engineered Fc region antagonizes FCGRT-mediated pathways, particularly interfering with IgG recycling via the neonatal Fc receptor. This disruption leads to accelerated clearance of pathogenic IgG antibodies implicated in autoimmune disorders, thereby reducing autoantibody-driven tissue damage. The nanobody platform further offers flexibility for future development into antibody-drug conjugates or bispecific formats, highlighting its potential as a modular therapeutic system adaptable to evolving clinical needs.

Autoimmune Disease

Autoimmune diseases are a diverse group of disorders characterized by inappropriate immune responses against healthy tissues, resulting in chronic inflammation and progressive organ damage. These conditions encompass a broad spectrum, affecting millions globally and imposing significant personal and socioeconomic burdens. Current mainstay treatments include corticosteroids, immunosuppressants, biologics, and targeted therapies; while these can control disease activity, they may carry notable side effects and are not always universally effective. The unmet needs in this field include safer long-term options, durable remissions, and therapies addressing resistant or relapsing cases. By precisely modulating key pathways through ALB and FCGRT, VHH-P257 has the potential to offer refined immune control, reduced adverse events, and improved patient outcomes in autoimmune disease management.